



December 22, 2014

Company Name	3 - D Matrix, Ltd.
Address	3-2-4, Kojimachi, Chiyoda, Tokyo
President	Kentaro Takamura
Code Number	7777
Contact	Director Tomoyuki Arai
T E L	+81 3 (3511)3440

Absorbable Hemostat “PuraStat®”
Commencement of clinical use in the field of endoscopy

The 3-D Matrix group has been working towards starting clinical use of absorbable hemostat “PuraStat®” since obtaining CE marking for the product on January 14, 2014. The company hereby announces that on December 17, 2014, clinical use of the product has commenced at the Edouard Herriot Hospital in France, one of the major markets for the product in Europe.

Edouard Herriot Hospital, Hepato-Gastroenterology Department, Thierry Ponchon, M.D, Ph.D., conducted the clinical use to control bleeding during an Endoscopic Submucosal Dissection and to prevent post-operative bleeding. Edouard Herriot Hospital is a flagship hospital conducting approximately 900 Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection procedures annually.

Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD) are endoscopic techniques developed to resect adenoma of the gastrointestinal tract and early stage cancer, and contribute to keeping Quality of Life (QOL) of patients as a less invasive therapy. PuraStat® is a suitable liquid-type hemostat for endoscopic techniques using catheter.

With the commencement of clinical use, the company aims to further promote clinical use of PuraStat® in our core European markets, and expand the distribution of the product through an exclusive agreement with a marketing partner.

This announcement does not influence the earning forecast of the company at this moment.